<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123734</url>
  </required_header>
  <id_info>
    <org_study_id>CAN/US-001-II-DVT</org_study_id>
    <nct_id>NCT00123734</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis</brief_title>
  <official_title>Phase II Clinical Trial to Evaluate the Accuracy of Anti-Fibrin Humanized Monoclonal Antibody (DI-DD3B6/22-80B3) Fab' Protein Fragment (ThromboView) Conjugated With Technetium-99m in the Detection of Deep Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agen Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agen Biomedical</source>
  <brief_summary>
    <textblock>
      The assessment of patients with suspected deep vein thrombosis (DVT) is a common clinical
      scenario that, despite major advances in diagnostic testing, continues to be challenging.

      The diagnosis of DVT remains problematic in:

        -  patients with suspected first DVT who have a moderate or high pre-test probability (PTP)
           for DVT and a normal compression ultrasound (CUS);

        -  patients with suspected recurrent DVT; and

        -  patients in whom CUS or contrast venography is technically difficult or not feasible due
           to patient characteristics.

      In patients with suspected first DVT who have a moderate or high PTP and a normal CUS, DVT
      occurs in up to 10% of cases. Thus, additional diagnostic testing is required, such as
      venography or serial CUS, so that DVT is not missed, but these approaches are costly and
      invasive.

      In patients with suspected recurrent DVT, currently used diagnostic approaches are
      problematic because they all have limitations in differentiating old disease from true
      recurrent disease.

      CUS is technically difficult in selected patients, particularly those who are obese.

      Contrast venography is the gold standard diagnostic test for DVT to which all other
      diagnostic venous imaging modalities for DVT are compared and judged. The Food and Drug
      Administration (FDA) requires that a new diagnostic test for DVT be assessed against
      venography.

      [99mTc] ThromboView® is a novel diagnostic test based on a 99mTc-labeled monoclonal antibody
      specific for D-dimer fragments of cross-linked fibrin that are found in acute DVT. After
      intravenous injection of [99mTc] ThromboView®, there is uptake of the monoclonal antibody by
      acute, D-dimer rich, venous thrombi. This is visualized with nuclear medicine imaging as an
      area of increased radioisotope activity that corresponds to the location of DVT.

      Based on the biologic and imaging characteristics of [99mTc] ThromboView®, this diagnostic
      test has the potential to:

        -  identify small non-occlusive proximal DVT or distal DVT in patients with a moderate or
           high PTP and normal CUS;

        -  differentiate old from new DVT in patients with suspected recurrent DVT;

        -  diagnose or exclude DVT in patients in whom CUS is not technically feasible; and

        -  provide an alternative to venography that is non-invasive, has no contrast-related
           toxicity and is easily administered.

      The present study is the first phase II clinical trial of [99mTc] ThromboView® in patients
      with suspected initial or recurrent DVT in whom DVT has been confirmed or excluded by
      venography. A phase II clinical trial to investigate the diagnostic accuracy of [99mTc]
      ThromboView® is justified because:

        -  ThromboView® was well tolerated, with no significant toxicity in studies involving
           animals and healthy volunteers; and

        -  it has shown promise in Phase I trials as a non-invasive diagnostic test for acute DVT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date>May 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT</measure>
    <time_frame>May 2007</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To Provide Estimates of the Sensitivity of [99mTc] ThromboView® in Patients With Confirmed Initial DVT.</measure>
    <time_frame>September 2005</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Suspected Recurrent DVT in Whom Disease Recurrence Has Been Excluded</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Provide Estimates of the Specificity of [99mTc] ThromboView® for Imaging Suspected Proximal Initial DVT</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Provide Estimates of the Sensitivity of [99mTc] ThromboView® for Imaging Suspected Proximal Initial DVT</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Provide Estimates of the Specificity of [99mTc] ThromboView® for Imaging Suspected Distal Initial DVT</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Provide Estimates of the Sensitivity of [99mTc] ThromboView® for Imaging Suspected Distal Initial DVT</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Provide Estimates of the Sensitivity and Specificity of [99mTc] ThromboView® for DVT at the 1-Hour and 3-Hour Imaging Time Points</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">94</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ThromboView</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult man or woman, aged ≥18 years, presenting with suspected lower-limb initial or
             recurrent DVT.

          -  Moderate or high pre-test probability (PTP) for DVT.

          -  Onset of symptoms occurred within the last 7 days.

          -  Women of childbearing potential to have a negative pregnancy test as determined by
             measuring serum β-hCG levels at time of study enrolment.

        Exclusion Criteria:

          -  Receiving anticoagulant therapy at therapeutic doses for &gt;3 days.

          -  Life expectancy &lt;3 months.

          -  Patient with a renal transplant.

          -  Renal dysfunction: serum creatinine &gt;1.5x upper limit of normal range.

          -  Hepatic dysfunction: serum transaminases &gt;3x upper limit of normal range.

          -  Current pregnancy or lactation; or conception intended within 90 days of enrolment

          -  Of childbearing potential and unwilling to use adequate contraception for 30 days
             following enrolment

          -  Unable to undergo lower limb ascending venography on symptomatic leg(s).

          -  Allergy or other contraindication to intravenous contrast dye.

          -  Prior exposure to murine or humanized antibodies.

          -  Prior imaging studies with: I131 within the last month; In111 or Ga67 within the last
             2 weeks; Tc99m labelled RBCs, WBCs or albumin within the last 48 hours; Tc99m or F18
             within the last 24 hours; prior non-imaging, non-therapeutic nuclear medicine studies
             with I131 (eg., 24-hour RAI uptake) within the last 2 weeks.

          -  Previous participation in the present study.

          -  Geographic inaccessibility that precludes follow-up visits.

          -  Patient is unwilling or unable to provide informed consent.

          -  Patient is unsuitable for the study, at the Study Investigator's discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Douketis, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff Ginsberg, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Centre</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>82103-9378</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma, Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University, Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henderson General Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu Du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de L'Universite Laval</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2005</study_first_submitted>
  <study_first_submitted_qc>July 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2005</study_first_posted>
  <results_first_submitted>July 9, 2009</results_first_submitted>
  <results_first_submitted_qc>July 9, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2009</results_first_posted>
  <last_update_submitted>July 9, 2009</last_update_submitted>
  <last_update_submitted_qc>July 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>94 participants were enrolled into the study. The first participant was enrolled on 4 March 2005, and the last participant was enrolled on 6 February 2006. All participants were enrolled in hosptial.</recruitment_details>
      <pre_assignment_details>12 participants did not recieve study drug (6 had no venography, 3 withdrew consent, 2 had an alternate diagnosis and 1 was a dropout).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dropout</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.12" spread="15.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT</title>
        <time_frame>May 2007</time_frame>
        <population>Number of participants with suspected initial DVT with evaluable images</population>
        <group_list>
          <group group_id="O1">
            <title>1 Hour Image Set</title>
            <description>Review of whole leg 1 hour images</description>
          </group>
          <group group_id="O2">
            <title>3 Hour Image Set</title>
            <description>Review of 3 hour whole leg images</description>
          </group>
          <group group_id="O3">
            <title>15 Min and 1 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 1 hour images in combination</description>
          </group>
          <group group_id="O4">
            <title>15 Minute and 3 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 3 hour images in combination</description>
          </group>
        </group_list>
        <measure>
          <title>To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT</title>
          <population>Number of participants with suspected initial DVT with evaluable images</population>
          <units>% Specificity</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="58.0" upper_limit="89.0"/>
                    <measurement group_id="O2" value="65.4" lower_limit="46.2" upper_limit="80.6"/>
                    <measurement group_id="O3" value="100" lower_limit="87.1" upper_limit="100"/>
                    <measurement group_id="O4" value="96.2" lower_limit="81.1" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Suspected Recurrent DVT in Whom Disease Recurrence Has Been Excluded</title>
        <time_frame>May 2007</time_frame>
        <population>Number of participants with suspected recurrent DVT with evaluable images</population>
        <group_list>
          <group group_id="O1">
            <title>1 Hour Image Set</title>
            <description>Review of whole leg 1 hour images</description>
          </group>
          <group group_id="O2">
            <title>3 Hour Image Set</title>
            <description>Review of 3 hour whole leg images</description>
          </group>
          <group group_id="O3">
            <title>15 Min and 1 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 1 hour images in combination</description>
          </group>
          <group group_id="O4">
            <title>15 Minute and 3 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 3 hour images in combination</description>
          </group>
        </group_list>
        <measure>
          <title>To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Suspected Recurrent DVT in Whom Disease Recurrence Has Been Excluded</title>
          <population>Number of participants with suspected recurrent DVT with evaluable images</population>
          <units>% Specificity</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="15.2" upper_limit="64.6"/>
                    <measurement group_id="O2" value="72.7" lower_limit="43.4" upper_limit="90.3"/>
                    <measurement group_id="O3" value="63.6" lower_limit="35.4" upper_limit="84.8"/>
                    <measurement group_id="O4" value="72.7" lower_limit="43.4" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Provide Estimates of the Specificity of [99mTc] ThromboView® for Imaging Suspected Proximal Initial DVT</title>
        <time_frame>May 2007</time_frame>
        <population>Number of participants with suspected initial DVT with evaluable images</population>
        <group_list>
          <group group_id="O1">
            <title>1 Hour Image Set</title>
            <description>Review of whole leg 1 hour images</description>
          </group>
          <group group_id="O2">
            <title>3 Hour Image Set</title>
            <description>Review of 3 hour whole leg images</description>
          </group>
          <group group_id="O3">
            <title>15 Min and 1 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 1 hour images in combination</description>
          </group>
          <group group_id="O4">
            <title>15 Minute and 3 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 3 hour images in combination</description>
          </group>
        </group_list>
        <measure>
          <title>To Provide Estimates of the Specificity of [99mTc] ThromboView® for Imaging Suspected Proximal Initial DVT</title>
          <population>Number of participants with suspected initial DVT with evaluable images</population>
          <units>% Specificity</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="69.4" upper_limit="94.5"/>
                    <measurement group_id="O2" value="70.0" lower_limit="52.1" upper_limit="83.3"/>
                    <measurement group_id="O3" value="100" lower_limit="88.3" upper_limit="100"/>
                    <measurement group_id="O4" value="96.7" lower_limit="83.3" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Provide Estimates of the Sensitivity of [99mTc] ThromboView® for Imaging Suspected Proximal Initial DVT</title>
        <time_frame>May 2007</time_frame>
        <population>Number of participants with suspected initial DVT with evaluable images</population>
        <group_list>
          <group group_id="O1">
            <title>1 Hour Image Set</title>
            <description>Review of whole leg 1 hour images</description>
          </group>
          <group group_id="O2">
            <title>3 Hour Image Set</title>
            <description>Review of 3 hour whole leg images</description>
          </group>
          <group group_id="O3">
            <title>15 Min and 1 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 1 hour images in combination</description>
          </group>
          <group group_id="O4">
            <title>15 Minute and 3 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 3 hour images in combination</description>
          </group>
        </group_list>
        <measure>
          <title>To Provide Estimates of the Sensitivity of [99mTc] ThromboView® for Imaging Suspected Proximal Initial DVT</title>
          <population>Number of participants with suspected initial DVT with evaluable images</population>
          <units>% Sensitivity</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="23.1" upper_limit="63.7"/>
                    <measurement group_id="O2" value="90.0" lower_limit="69.9" upper_limit="97.2"/>
                    <measurement group_id="O3" value="15.8" lower_limit="5.5" upper_limit="37.6"/>
                    <measurement group_id="O4" value="84.2" lower_limit="62.4" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Provide Estimates of the Sensitivity of [99mTc] ThromboView® in Patients With Confirmed Initial DVT.</title>
        <time_frame>September 2005</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Hour Image Set</title>
            <description>Review of whole leg 1 hour images</description>
          </group>
          <group group_id="O2">
            <title>3 Hour Image Set</title>
            <description>Review of 3 hour whole leg images</description>
          </group>
          <group group_id="O3">
            <title>15 Min and 1 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 1 hour images in combination</description>
          </group>
          <group group_id="O4">
            <title>15 Minute and 3 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 3 hour images in combination</description>
          </group>
        </group_list>
        <measure>
          <title>To Provide Estimates of the Sensitivity of [99mTc] ThromboView® in Patients With Confirmed Initial DVT.</title>
          <units>% Sensitivity</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" lower_limit="21.5" upper_limit="55.8"/>
                    <measurement group_id="O2" value="74.1" lower_limit="55.3" upper_limit="86.8"/>
                    <measurement group_id="O3" value="11.1" lower_limit="3.9" upper_limit="28.1"/>
                    <measurement group_id="O4" value="59.3" lower_limit="40.7" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Provide Estimates of the Specificity of [99mTc] ThromboView® for Imaging Suspected Distal Initial DVT</title>
        <time_frame>May 2007</time_frame>
        <population>Number of participants with suspected initial DVT with evaluable images</population>
        <group_list>
          <group group_id="O1">
            <title>1 Hour Image Set</title>
            <description>Review of whole leg 1 hour images</description>
          </group>
          <group group_id="O2">
            <title>3 Hour Image Set</title>
            <description>Review of 3 hour whole leg images</description>
          </group>
          <group group_id="O3">
            <title>15 Min and 1 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 1 hour images in combination</description>
          </group>
          <group group_id="O4">
            <title>15 Minute and 3 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 3 hour images in combination</description>
          </group>
        </group_list>
        <measure>
          <title>To Provide Estimates of the Specificity of [99mTc] ThromboView® for Imaging Suspected Distal Initial DVT</title>
          <population>Number of participants with suspected initial DVT with evaluable images</population>
          <units>% Specificity</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="78.0" upper_limit="98.1"/>
                    <measurement group_id="O2" value="89.7" lower_limit="73.6" upper_limit="96.4"/>
                    <measurement group_id="O3" value="100" lower_limit="88.3" upper_limit="100"/>
                    <measurement group_id="O4" value="96.6" lower_limit="82.8" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Provide Estimates of the Sensitivity of [99mTc] ThromboView® for Imaging Suspected Distal Initial DVT</title>
        <time_frame>May 2007</time_frame>
        <population>Number of participants with suspected initial DVT with evaluable images</population>
        <group_list>
          <group group_id="O1">
            <title>1 Hour Image Set</title>
            <description>Review of whole leg 1 hour images</description>
          </group>
          <group group_id="O2">
            <title>3 Hour Image Set</title>
            <description>Review of 3 hour whole leg images</description>
          </group>
          <group group_id="O3">
            <title>15 Min and 1 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 1 hour images in combination</description>
          </group>
          <group group_id="O4">
            <title>15 Minute and 3 Hour Image Set</title>
            <description>Review of whole leg 15 minute and 3 hour images in combination</description>
          </group>
        </group_list>
        <measure>
          <title>To Provide Estimates of the Sensitivity of [99mTc] ThromboView® for Imaging Suspected Distal Initial DVT</title>
          <population>Number of participants with suspected initial DVT with evaluable images</population>
          <units>% Sensitivity</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="7.3" upper_limit="38.5"/>
                    <measurement group_id="O2" value="40.9" lower_limit="23.3" upper_limit="61.3"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="14.9"/>
                    <measurement group_id="O4" value="36.4" lower_limit="19.7" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Provide Estimates of the Sensitivity and Specificity of [99mTc] ThromboView® for DVT at the 1-hour and 3-hour Imaging Time Points</title>
        <time_frame>May 2007</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
        </group>
      </group_list>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Michael Gerometta</name_or_title>
      <organization>AGEN Biomedical Ltd</organization>
      <phone>+61 408 885 416</phone>
      <email>mgerometta@agenix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

